Rakovina Therapeutics Inc · TSXV:RKV
Rakovina Therapeutics — Investor Presentation (November 2025)
20 slides from Rakovina Therapeutics's investor presentation, November 2025
Slide 1: Advancing Cancer Care with the Precision & Power of AI
ADVANCING CANCER CARE WITH THE PRECISION & POWER OF AI TSX.V: RKV Investor Presentation | Q4 2025
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the investors who will pa
Slide 3: Rakovina's Mission – Improve the Speed and Accuracy of Oncology Drug Development
RAKOVINA’S MISSION – IMPROVE THE SPEED AND ACCURACY OF ONCOLOGY DRUG DEVELOPMENT Rakovina is developing DNA Damage Response (DDR) cancer therapies With access to robust Artificial Intelligence (AI) platforms, Rakovina can speed up discovery timelines, increase precision and greatly reduce the risk a
Slide 4: AI Powered Drug Development
AI POWERED DRUG DEVELOPMENT Patients cannot wait years to get the treatment they need today Traditional Drug Development AI Driven Drug Development Thousands of potential drug candidates BILLIONS of potential drug candidates DEVELOPMENT PATH STAGE 1 Selecting a STAGE 1 Clinical Lead STAGE 2 STAGE 2
Slide 5: Experienced Team with a Track Record of Success
EXPERIENCED TEAM WITH A TRACK RECORD OF SUCCESS A team with deep expertise in drug discovery, preclinical and clinical development and pharma partnering JEFFREY BACHA, BSC, MBA ARTEM CHERKASOV, PHD Executive Chairman/Director SAB/Senior AI & Medicinal Chemistry Advisor • 25 years of experience as fo
Slide 6: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Rakovina’s globally respected Scientific Advisory Board provides the strategic insight and credibility to attract partners and investors DENNIS BROWN, PHD WANG SHEN, PHD Chair, Scientific Advisory Board (SAB)/Director SAB/Senior Medicinal Chemistry Advisor • Involved in can
Slide 7: Rakovina's AI: Deep Docking & Enki How It Works
RAKOVINA’S AI: HOW IT WORKS DEEP DOCKINGTM & ENKITM Deep Docking and Enki are distinct computational Exclusive access to Deep modeling techniques that Docking AI platform1 for DNA- rapidly evaluate billions of damage response (DDR) targets compounds to identify novel therapeutic drug candidates. Col
Slide 8: Deep Docking AI Platform: Real-World Impact on COVID-19
DEEP DOCKING AI PLATFORM1: REAL-WORLD IMPACT ON COVID-19 The team behind Deep Docking partnered with Nvidia, Dell and UBC Advanced Research Computing (ARC) to identify potential COVID-19 therapeutics from large libraries. “Even with a supercomputer, it would take years to screen billions of compound
Slide 9: DNA-Damage Response (DDR)
DNA-DAMAGE RESPONSE (DDR) • DDR pathways repair DNA damage, and when they fail, mutations accumulate and drive cancer. • Cancer cells with DDR-mutations rely on backup repair pathways; DDR drugs block these, causing selective cancer cell death. • PARP inhibitors validate DDR as a drug class, with 30
Slide 10: Investments in DNA-Damage Response by Multi-National Pharmaceutical Corporations
INVESTMENTS IN DNA-DAMAGE RESPONSE BY MULTI-NATIONAL PHARMACEUTICAL CORPORATIONS RECENT DDR TRANSACTIONS Oct 2023 PARP-inhibitor • $1.5B ($169M upfront) • FDA status at signing: phase 1 License Agreement Jun 2022 ATR-inhibitor • $1.2B ($125M upfront) • FDA status at signing: preclinical License Agre
Slide 11: Rakovina Therapeutics' Drug Development Portfolio
RAKOVINA THERAPEUTICS’ DRUG DEVELOPMENT PORTFOLIO Development Stage DDR Pipeline Indication Lead Clinical Discovery Pre-clinical Optimization Trials PARP-resistant JV for co-development kt-3283 (PARP / HDAC) adult & childhood progressing with Saudi- cancers based NanoPalm Inc. kt-2000AI (PARP1) Soli
Slide 12: kt-3283 Development
kt-3283 DEVELOPMENT PARP-HDAC dual function inhibitor Confirmed activity against PARP1, PARP2 and HDAC Enhanced efficacy against Ewing sarcoma, breast cancer, ovarian cancer, and prostate cancer cells in vitro Induction of cell cycle arrest and DNA damage in Ewing sarcoma cells Reduced cell
Slide 13: First AI DDR Target: A CNS Penetrant Selective Inhibitor of PARP1
FIRST AI DDR TARGET: A CNS PENETRANT SELECTIVE INHIBITOR OF PARP1 • PARP inhibitors are a type of drug that works by preventing certain types of cancer cells from repairing damaged DNA, committing them to die • 1st generation PARP-1/2 inhibitors have achieved commercial success in the treatment of c
Slide 14: kt-2000AI Program
kt-2000AI PROGRAM CNS-penetrant PARP1-selective inhibitor Completed custom synthesis and functional assessment of 389 compounds against PARP1 and PARP2 Ongoing synthesis and assessment of an additional 30 compounds Data from 1st round screening being used for further AI compound discovery CNS-
Slide 15: Second AI DDR Target: A CNS Penetrant Selective Inhibitor of ATR
SECOND AI DDR TARGET: A CNS PENETRANT SELECTIVE INHIBITOR OF ATR • ATR (ataxia telangiectasia and Rad3-related protein) is a critical kinase that senses and responds to DNA damage • Some cancer cells rely heavily on ATR for survival. Inhibiting ATR selectively leads to tumor cell death • Several lar
Slide 16: kt-5000AI Program
kt-5000AI PROGRAM CNS-penetrant ATR inhibitor Partnered with Vancouver-based Variational AI Shortlist of 137 molecules predicted to be potent, selective, CNS-penetrant ATR inhibitors Synthesis and functional assessment of 43 candidate compounds to date Further characterization of 10 compounds
Slide 17: Recent Accomplishments & Upcoming Milestones
RECENT ACCOMPLISHMENTS & UPCOMING MILESTONES 2025 - Corporate 2025 - Pipeline Con’t 2026 - Upcoming • Listed on the Frankfurt stock kt-2000AI Series • Completion of NanoPalm JV exchange • 398 compounds evaluated; 10 and launch of R&D work in • Raised $4.9M CAD (to date) hit candidates identified tum
Slide 18: Market Summary
MARKET SUMMARY EXCHANGE TSX Venture Exchange (TSXV) OWNERSHIP SUMMARY SYMBOL RKV Edison Oncology SECTOR / INDUSTRY Biopharmaceuticals / Oncology Holding Corp. 12% YEAR HIGH / LOW CAD $2.30 / $0.135 Reporting Insiders, 4% SHARES OUTSTANDING 21,148,039 Institution / FULLY DILUTED 39,638,846 Retail 66%
Slide 19: Why Invest in Rakovina Therapeutics
WHY INVEST IN RAKOVINA THERAPEUTICS A new paradigm in drug discovery and therapeutic intervention to treat cancer. $18B ADDRESSABLE MARKET BY 20301 Broad cancer application targeting solid tumors that harbor a VALIDATED AI TECHNOLOGY DNA-Damage response defect. Deep Docking platform developed drug l
Slide 20: ir@rakovinatherapeutics.com rakovinatherapeutics.com Suite 720, 999 West Broadway
ir@rakovinatherapeutics.com rakovinatherapeutics.com Suite 720, 999 West Broadway Vancouver, British Columbia CanadaTSX.V: V5Z 1K5 RKV / 20
Rakovina Therapeutics — Investor Presentation (November 2025) on 6ix